Subtype
Low Grade Glioma
CI-CAN-00003062LGGExplore in graph →
Non-malignant115 active trials62 evidence items
- NCIt
- C132067
- OncoTree
- LGGNOS
- DOID
- 0080829
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00003062LGGExplore in graph →
Clinical trials
324 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | not yet recruiting | Phase 3 | 140 | Nuvation Bio Inc.INDUSTRY | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07004075 | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration | not yet recruiting | Phase 3 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Jun 4, 2025 |
| clinicaltrials |
Data updated 22 days agoSource updated Jul 17, 2026source: clinicaltrials